Immunomedics, Inc., a biopharmaceutical company, develops monoclonal antibody-based products for the treatment of cancer, autoimmune, and other serious diseases. Its lead product candidate is epratuzumab. The company was founded in 1982 and is headquartered in Morris Plains, New Jersey. It has a majority owed subsidiary IBC Pharmaceuticals.